Owing to advances in radiotherapy, the physical properties of radiation can be optimized to
enable individualized treatment; however, optimization is rarely based on biological …

Background Nearly one-third of patients with prostate cancer (PCa) experience biochemical
recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant …

Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …

Prostate cancer has the widest racial disparities of any cancer, and these disparities appear
at every stage of the cancer continuum. This review focuses on the disparities in prostate …

The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

PURPOSE It remains unknown whether or not short-term androgen deprivation (STAD)
improves survival among men with intermediate-risk prostate cancer (IRPC) treated with …

Background The Decipher genomic classifier (GC) has shown to independently
prognosticate outcomes in prostate cancer. The objective of this study was to validate the …

Biochemical recurrence develops in almost one-third of men with prostate cancer after
treatment with local therapy. There are numerous options for management, including …

Significant progress has been made in genetic and genomic testing for prostate cancer
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …

Background Personalized genomic classifiers have transformed the management of
prostate cancer (PCa) by identifying the most aggressive subsets of PCa. Nevertheless, the …